BeStock  
Stocks › Biotechnology › CRMD

CorMedix CRMD

US equityMarket cap rank #3659Biotechnology
$5.27 +$0.19 (+3.74%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $5.32 +0.95%
Open$4.96
Prev close$5.08
Day range$4.95 – $5.32
Volume3.61M
Market cap$419.16M
P/E (TTM)8.2
Dividend yield–

Earnings

Average move on report day±13.1%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+30.2%
Worst reaction-31.8%

Stock move on the day after each report

-2.8%2023/Q4-5.2%2024/Q1+30.2%2024/Q2-22.5%2024/Q3-31.8%2024/Q4+23.6%2025/Q1-9.5%2025/Q2+2.1%2025/Q3-11.5%2025/Q4+5.7%2026/Q1+14.6%2026/Q2-8.7%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q312 Nov 2026Pre Market±20.2%-8.68%Within range
2026/Q213 Aug 2026Pre Market±13.5%+14.65%Bigger than priced
2026/Q114 May 2026Pre Market±15.0%+5.73%Within range
2025/Q45 Mar 2026Pre Market±14.9%-11.52%Within range
2025/Q312 Nov 2025Pre Market±13.6%+2.06%Within range
2025/Q27 Aug 2025Pre Market±18.3%-9.54%Within range
2025/Q16 May 2025Pre Market±20.7%+23.59%Bigger than priced
2024/Q425 Mar 2025Pre Market±21.4%-31.85%Bigger than priced
2024/Q330 Oct 2024Pre Market±22.0%-22.51%Bigger than priced
2024/Q214 Aug 2024Pre Market±19.1%+30.16%Bigger than priced
2024/Q19 May 2024Pre Market±16.5%-5.17%Within range
2023/Q412 Mar 2024Pre Market±20.0%-2.84%Within range
2023/Q314 Nov 2023After Market±44.9%+6.39%Within range
2023/Q28 Aug 2023Pre Market±20.6%+7.94%Within range
2023/Q115 May 2023After Market±19.5%-13.40%Within range
2022/Q430 Mar 2023Pre Market±27.6%+13.11%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • DefenCath$66.12M 66.6%
  • Melinta Portfolio$28.22M 28.4%
  • Contract revenue$4.97M 5.0%

Latest reported quarter: Q3, ended Sep 2026

Revenue$51.26M-50.8% YoY
Operating profit-$6.62M-112.9% YoY
Net profit-$14.72M-113.6% YoY
Diluted EPS-$0.19-115.1% YoY
Free cash flow$87.79M+189.2% YoY
Operating cash flow$89.70M

Revenue, last 8 quarters

$31.2MDec '24$39.1MMar '25$39.7MJun '25$104.3MSep '25$128.6MDec '25$127.4MMar '26$99.3MJun '26$51.3MSep '26

Net profit, last 8 quarters

$13.5MDec '24$20.6MMar '25$19.8MJun '25$108.6MSep '25$14.0MDec '25$38.6MMar '26$26.0MJun '26$-14.7MSep '26

Profitability & balance sheet

Gross margin77.0%
Operating margin39.4%
Net margin15.6%
Return on equity15.1%
Return on assets7.5%
Return on invested capital11.1%
Current ratio2.43
Liabilities / assets49.7%
Cash & investments$355.15M
Total debt$145.42M
Net cash (debt)$209.73M
Free cash flow / sales76.2%

Discussion

No comments yet — be the first to weigh in on CRMD.

Sign in to join the discussion.

Scroll to Top